傳富衛美國上市計劃因監管問題未獲SEC批准
李澤楷旗下保險公司富衛集團(FWD)早前已提交美國上市申請,惟據《彭博通訊社》近日報道指,由於美國監管機構對中國監管風險的審查,富衛的IPO申請至今仍未獲得最終批准,預期未能在今年內上市。
報道引述消息人士指,富衛的IPO計劃停滯不前,主要由於美國證券交易委員會對中國監管範圍存有疑問,曾要求富衛回覆中國政府是否可以將監管權力擴大到以香港為基地的富衛。另外,富衛同時面臨投資者對監管風險和估值的擔憂。
富衛原預期在紐約上市,目標集資約20億至30億美元。消息指富衛未有放棄到美國上市的計劃,可能會在日後重啟計劃,或選擇在香港等不同市場出售股票或通過股權出售等其他方式籌集資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.